Who is eligible for clinical trial NCT07612293?

Participants must meet the protocol's inclusion criteria for Thyroid Gland Medullary Carcinoma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07612293 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-27

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection (NCT07612293)

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection for the Treatment of Sporadic Medullary Thyroid Cancer, STAGE-MTC Trial

🟡 Not Yet Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Jonsson Comprehensive Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are limited to the thyroid are managed in the same way, complete surgical removal of the entire thyroid gland (total thyroidectomy) with surgical removal of lymph nodes and other tissues on both sides of the neck (bilateral central neck dissection). Total thyroidectomy and bilateral central neck dissection carry a high risk of complications, and total thyroidectomy requires patients to take lifelong thyroid hormone replacement therapy, which can impact quality of life. Research has shown that patients with sporadic MTC do not have a high risk of developing MTC in the remaining normal thyroid tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which removes only the lobe of the thyroid gland that is affected by cancer as well as the lymph nodes and other tissues from the affected side of the neck. Thyroid lobectomy with ipsilateral central neck dissection may be a safer, more tolerable, and/or more effective way to treat sporadic MTC.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (11 items).

Location: UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California

Age range: 18 Years

🧪 Interventions in This Study

Biospecimen Collection (PROCEDURE)
FDG-Positron Emission Tomography and Computed Tomography Scan (PROCEDURE)
Ga-68 PET/CT Scan (PROCEDURE)
Neck Dissection (PROCEDURE)
Neck Dissection (PROCEDURE)
Surveillance (BEHAVIORAL)
Thyroid Lobectomy (PROCEDURE)
Thyroidectomy (PROCEDURE)
Ultrasound Imaging (PROCEDURE)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female ≥ 18 years of age at time of diagnosis
Documentation of a medullary thyroid cancer diagnosis as evidenced by:
Thyroid fine needle aspiration biopsy with cytologist consistent with medullary thyroid cancer
Indeterminate cytology from thyroid fine needle aspiration with elevated serum calcitonin OR thyroid molecular testing consistent with medullary thyroid cancer
Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study
Appropriate candidate for thyroid lobectomy and/or total thyroidectomy

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Indication for total thyroidectomy unrelated to medullary thyroid cancer:
Graves' disease
Symptomatic multinodular goiter
Contralateral symptomatic benign nodules
Ultrasound findings consistent with:
Cervical lymphadenopathy involving lateral neck or contralateral central neck
Suspicious thyroid nodules \> 1 cm that are Thyroid Imaging Reporting and Data Systems 2 (TIRADS2) or higher without fine needle aspiration (FNA)
Pure cystic and spongiform nodules do not require FNA
Patients with nodules that meet criteria above can elect to undergo FNA, and may enroll in study if benign cytology is noted
Identification of germline RET mutation on preoperative genetic testing

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California

📞 Contact the Study Coordinator

Phone: (310) 206-9145

Email: EGHughes@mednet.ucla.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Thyroid Gland Medullary Carcinoma

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers — Houston, Texas

Explore by condition: All Thyroid Gland Medullary Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗